Tag: patients

Robotics at Zydus Hospitals, Gujarat are revolutionising Joint Replacement Surgeries in the ElderlyAHMEDABAD, India, June 11, 2026 /PRNewswire/ -- Osteoarthritis and chronic joint degeneration affect...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Scholarship aims to support students of color pursuing careers in dentistry to improve access to representative oral care across the state. SEATTLE, June 10,...

In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...

OTTAWA, ON, June 10, 2026 /CNW/ - The giants of tech and online media have been mining profit from the attention of Canadian kids for...

PHILADELPHIA, June 10, 2026 /PRNewswire/ -- Following the Philadelphia City Council's vote to pass a bill classifying kratom and hemp-derived products as "intoxicating substances,"...

Detailed Program Agenda Released for 2026 Scientific SessionsBOULDER, Colo., June 10, 2026 /PRNewswire/ -- The American Society for Preventive Cardiology (ASPC) announces its 2026...

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

RALEIGH, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- The AKC Canine Health Foundation (CHF), in collaboration with the American Kennel Club (AKC®), is pleased to announce that the Cornell University College of Veterinary Medicine has matched its first resident funded through the second annual AKC/AKC CHF Canine Sports Medicine & Rehabilitation Residency Program award. Dr. Gabriela Medrano will begin her training with the program this fall.

Drs. Michael N. Dudley, Keith A. Micetich, and Jürgen B. Bulitta join advisory board of renowned infectious disease leaders at Fedora Pharmaceuticals.